Maria Laura Bolognesi

Prof. Maria Laura Bolognesi

orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2018 in Clinical and Translational Medicine
Verified
Journal Article
Open access
PDF file
Rona RamsayRona Ramsay
Rona Ramsay
Marija Popović-NikolićMarija Popović-Nikolić
Marija Popović-Nikolić
KNKatarina Nikolic
Katarina Nikolic
EUElisa Uliassi
Elisa Uliassi
MBMaria Laura Bolognesi
Maria Laura Bolognesi
Diseases of infection, of neurodegeneration (such as Alzheimer's and Parkinson's diseases), and of malignancy (cancers) have complex and varied causative factors. Modern drug discovery has the power to identify potential modulators for multiple targets from millions of compounds. Computational approaches allow the determination of the association of each compound with its target before chemical synthesis and biological testing is done. These approaches depend on the prior identification of clinically and biologically validated targets. This Perspective will focus on the molecular and computational approaches that underpin drug design by medicinal chemists to promote understanding and collaboration with clinical scientists.

30 November 2007 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MBMaria Laura Bolognesi
Maria Laura Bolognesi
ACAndrea Cavalli
Andrea Cavalli
Luca ValgimigliLuca Valgimigli
Luca Valgimigli
MBManuela Bartolini
Manuela Bartolini
MRMichela Rosini
Michela Rosini
CMCarlo Melchiorre
Carlo Melchiorre

9 April 2016 in ChemMedChem
Verified
Journal Article
Open access
PDF file
MBMaria Laura Bolognesi
Maria Laura Bolognesi
ACAndrea Cavalli
Andrea Cavalli
Promising promiscuity: Guest editors Maria Laura Bolognesi and Andrea Cavalli set the stage for this ChemMedChem Special Issue on Polypharmacology and Multitarget Drugs. They highlight cases in which a departure from the “one target, one drug” paradigm has proven advantageous, with single molecules that can engage two or more targets to address a given pathology. Articles in this issue underscore the importance of focusing ever more attention to polypharmacology in drug discovery efforts.

1 March 2013 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
MBMaria Laura Bolognesi
Maria Laura Bolognesi
Polypharmacology offers a model for the way drug discovery must evolve to develop therapies most suited to treating currently incurable diseases. It is driven by a worldwide demand for safer, more effective, and affordable medicines against the most complex diseases, and by the failures of modern drug discovery to provide these. Polypharmacology can involve combinations and/or multitarget drugs (MTD). Although not mutually exclusive, my premise is that MTDs have inherent advantages over combinations. This review article focuses on MTDs from a medicinal chemistry perspective. I will explore their use in current clinical practice, their likely application in the future, and the challenges to be overcome to achieve this goal.

23 September 2021 in Chemical Society Reviews
Verified
Journal Article
Closed access
PDF file
CEClaudia Espro
Claudia Espro
Emilia PaoneEmilia Paone
Emilia Paone
Francesco MaurielloFrancesco Mauriello
Francesco Mauriello
RGRoberto Gotti
Roberto Gotti
EUElisa Uliassi
Elisa Uliassi
Rafael LuqueRafael Luque
Rafael Luque
The aim of this tutorial review is to provide a general overview of processes, technologies and challenges in the production of pharmaceutical and bioactive compounds from food waste and lignocellulosic residues.

19 June 2020 in Medicinal Research Reviews
Verified
Journal Article
Closed access
PDF file
CAClaudia Albertini
Claudia Albertini
ASAlessandra Salerno
Alessandra Salerno
PPPedro de Sena Murteira Pinheiro
Pedro de Sena Murteira Pinheiro
MBMaria Laura Bolognesi
Maria Laura Bolognesi